Peter Kolkhof

This inventor holds 47 USPTO granted patents and 20 published patent applications, plus 4 CIPO patents and 25 EPO patents, primarily in Triazole Derivatives. Top assignees: Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft. Active years: 2000-2023.

USPTO Granted Patents = 47 (Patent Applications = 20)

% Patents Active = 36.2

CIPO Patents = 4 (Patent Applications = 15)

EPO Patents = 25 (Patent Applications = 34)

Average Co-Inventor Count = 7.9

ph-index = 7

Forward Citations = 140(Granted Patents)

Company Filing History:

20 out of 721

Bayer Intellectual Property Gmbh

patents

19 out of 386

Bayer Pharma Aktiengesellschaft

patents

5 out of 12,266

Bayer Aktiengesellschaft

patents

4. 3 out of 192

Bayer Schering Pharma Ag

patents

5. 1 out of 54

Bayer Animal Health Gmbh

patents

6. 1 out of 77

Bayer Healthcare Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

Areas of Expertise:

Triazole Derivatives

Mineralocorticoid Receptor Antagonists

Cardiovascular Diseases

Hematological Diseases

sGC Stimulators

Prodrugs

Phenyltriazole

Pyrazolones

Pyridinyltriazole

Aryltriazolones

HIF Inhibitors

Acetamido Compounds

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11684621 - Combination containing sGC stimulators and mineralocorticoid receptor antagonists (2023-06-27),

2. 11439628 - Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases (2022-09-13),

3. 11331314 - Amine substituted triazole derivatives and uses thereof (2022-05-17),

4. 11331308 - Combination containing sGC activators and mineralocorticoid receptor antagonists (2022-05-17),

5. 11298367 - Prodrugs of substituted triazole derivatives and uses thereof (2022-04-12),

6. 11230540 - Substituted triazole derivatives and uses thereof (2022-01-25),

7. 11173151 - Substituted triazole derivatives and uses thereof (2021-11-16),

8. 11149023 - Substituted triazole derivatives and uses thereof (2021-10-19),

9. 11091463 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2021-08-17),

10. 10927098 - Hydroxyalkyl-substituted triazole derivatives and uses thereof (2021-02-23),

11. 10918639 - Combination containing SGC stimulators and mineralocorticoid receptor antagonists (2021-02-16),

12. 10815205 - Amide-substituted phenyltriazole derivatives and uses thereof (2020-10-27),

13. 10800746 - Oxoalkyl-substituted phenyltriazole derivatives and uses thereof (2020-10-13),

14. 10526314 - Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof (2020-01-07),

15. 10525041 - Fluoroalkyl-substituted aryltriazole derivatives and uses thereof (2020-01-07),

Title: Peter Kolkhof: Innovator in Cardiovascular and Neuromuscular Treatments

Introduction: Peter Kolkhof, a prominent inventor based in Wuppertal, Germany, has made significant contributions to the field of medicinal chemistry and pharmacology through his 47 patents. His work primarily focuses on treatments for various cardiovascular and neuromuscular disorders.

Latest Patents: Kolkhof's recent innovations include a combination of soluble guanylate cyclase (sGC) stimulators and mineralocorticoid receptor antagonists (MRAs) aimed at treating a range of disorders. One patent specifically relates to the treatment and prophylaxis of cardiac, cardiovascular, renal, cardiorenal, pulmonary, cardiopulmonary, and fibrotic disorders using this combination. Another patent addresses the use of non-steroidal mineralocorticoid receptor antagonists, either alone or in combination with sGC stimulators or activators, to develop medicaments for preventing and treating muscular or neuromuscular diseases, particularly Duchenne Muscular Dystrophy (DMD).

Career Highlights: Throughout his career, Peter Kolkhof has worked with leading companies, including Bayer Intellectual Property GmbH and Bayer Pharma Aktiengesellschaft. His scientific and innovative contributions have positioned him as a key figure in pharmaceutical research.

Collaborations: In his professional journey, Kolkhof has collaborated with notable colleagues such as Elisabeth Pook and Carsten Schmeck. These partnerships have furthered his research and development efforts in the field of medical treatments.

Conclusion: Peter Kolkhof's extensive patent portfolio and collaborative work underscore his dedication to advancing medical science, particularly in the areas of cardiovascular health and neuromuscular diseases. His patents reflect a commitment to developing effective treatments, showcasing the importance of innovation in tackling complex health challenges.